Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 2
Ce profil est validé par 2 label.

Company

ExeVir Bio b.v

ExeVir Bio b.v_logo
30
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

ExeVir Bio, a spin out of VIB, is harnessing its Llama-derived antibody (VHH) technology platform to generate robust antiviral therapies providing broad protection against viruses with a lead candidate for SARS Cov-1&2.

Gent, Région flamande, Belgium

Send a message

Anglais

ExeVir Bio b.v

Anglais

ExeVir Bio, a spin out of VIB, the leading Belgium-based life sciences research institute, is harnessing its Llama-derived antibody (VHH) technology platform to generate robust antiviral therapies providing broad protection against viruses with a lead candidate for SARS Cov-1&2. To accelerate our lead, UCB, a multinational biopharmaceutical company, assisted in the generation of the lead candidate and is producing the GMP batches for clinical trials. Fund+, a leading EU Life...

See more

ExeVir Bio, a spin out of VIB, the leading Belgium-based life sciences research institute, is harnessing its Llama-derived antibody (VHH) technology platform to generate robust antiviral therapies providing broad protection against viruses with a lead candidate for SARS Cov-1&2. To accelerate our lead, UCB, a multinational biopharmaceutical company, assisted in the generation of the lead candidate and is producing the GMP batches for clinical trials. Fund+, a leading EU Life Sciences-focused investment firm in Belgium, led the 1st closing financing, pulling together a strong consortium including UCB Ventures, FPIM, V-Bio and VIB.

ExeVir Bio is using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat. Lead asset VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell. Its VHH format has particular advantages over convalescent derived antibodies including potential reduced risk of mutant escapes. This approach could be used both as a therapeutic and prophylactic. Therapeutic use could help slow viral replication in the lungs, reduce inflammation, and give patients valuable time to raise their own productive immune response. 

  • 1

    Followers

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not receive funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1479 Entities
ePitches EuroQuity
217 Entities

Communities

EUROQUITY BELGIUM
EuroQuity Belgium AT THE SERVICE OF BUSINESS GROWTH The community is reserved for growing Belgian companies and their partners: investors and business partners.
922 Members
Access2EIC – Seal of Excellence
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
2134 Members
InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2288 Members